ECS Botanics 70% revenue hike

Murray Meds to supply medicinal cannabis dried flower, concentrate and final dose oils to Australian cannabinoid company The customer distributes premium medicinal cannabinoid products and services ECS shareholders approved the acquisition of 100% of Murray Meds on 2 March, 2021 with settlement to occur in the near term ECS Botanics Holdings Ltd (ASX: ECS or…

Click here to listen to Managing Director, Alex Keach interview with Laurissa Smith on Tasmanian Country Hour about our new major medicinal cannabis project.

ECS Botanics subsidiary Murray Meds has signed a deal with Melbourne-based Releaf Dispensaries to supply the group with its dried cannabis flower. ECS food and wellness products are already stocked in Releaf’s St Kilda dispensary. The deal is expected to generate around A$590,000 in revenue for ECS over its 18-month term, with the option to…

Will Australians Turn to the Black Market Amid the Cannabis Shortage? Australians are running out of medical marijuana, and many will have nowhere to turn but the black market. The number of medical cannabis products being approved via the Special Access Scheme B-portal (SAS-B) continues to rise, with February’s numbers hitting an all-time high of over 8,000…

ECS Botanics’ new subsidiary extends supply agreement for its sun-kissed cannabis flower Just as they have done with fine wine, Aussies are choosing to consume home-grown marijuana rather than foreign imports, and ECS Botanics (ASX:ECS) is stepping up to the plate with its premium dried flower products. ECS’ new Victoria-based subsidiary, Murray Meds, this week extended its…

ECS Botanics plans major expansion of Tasmanian cannabis farm ECS Botanics (ASX: ECS) has submitted plans to the Office of Drug Control to expand its Tasmanian cannabis farm by more than 100 times its current area. If approved, ECS’ cannabis cultivation area would be expanded from 2,500sqm to 320,000sqm an Australian first according to managing…